| NCT07157956 | Convalife (Shanghai) Co., Ltd. | Advanced Solid Tumor | 2025-09-10 | PHASE1|PHASE2 |
| NCT06104618 | Mayo Clinic | Metastatic Penile Squamous Cell Carcinoma|Stage III Penile Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Unresectable Penile Squamous Cell Carcinoma | 2023-12-21 | PHASE2 |
| NCT06809140 | Matthew Galsky|Seagen Inc.|Astellas Pharma Inc|Merck Sharp & Dohme LLC|Icahn School of Medicine at Mount Sinai | Muscle Invasive Bladder Urothelial Carcinoma | 2025-04-07 | PHASE2 |
| NCT07484022 | Generate Biomedicines | Advanced Urothelial Cancer|Metastatic Urothelial Carcinoma | 2026-04 | PHASE1 |
| NCT07217496 | Vadim S Koshkin|ImmunityBio, Inc. | Metastatic Urothelial Carcinoma|Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma|Urothelial Cancer | 2026-02-15 | PHASE1 |
| NCT07421700 | Pfizer|Astellas Pharma Inc | Urothelial Cancer|Advanced+Metastatic Urothelial Cancer|Urothelial Carcinoma | 2026-03-11 | PHASE1|PHASE2 |
| NCT06434350 | M.D. Anderson Cancer Center | Advanced Bladder Cancer | 2024-10-10 | PHASE1|PHASE2 |
| NCT07347314 | National Cancer Center, Japan|Astellas Pharma Inc | Advanced Small Bowel Adenocarcinoma | 2025-11-04 | PHASE2 |
| NCT07475806 | Astellas Pharma Global Development, Inc.|Pfizer | Muscle-invasive Bladder Cancer | 2026-03-12 | PHASE2 |
| NCT07374549 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Advanced Urothelial Carcinoma | 2026-06-20 | PHASE2 |
| NCT03547973 | Gilead Sciences|Merck KGaA, Darmstadt, Germany | Metastatic Urothelial Cancer | 2018-08-13 | PHASE2 |
| NCT07110038 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Merck KGaA, Darmstadt, Germany|Astellas Pharma GmbH|University Hospital Tübingen | Penile Squamous Cell Carcinoma (PSCC) | 2025-12-16 | PHASE2 |
| NCT06356155 | University of Michigan Rogel Cancer Center | Urothelial Carcinoma | 2025-07-22 | PHASE2 |
| NCT06906822 | Grupo Espa?ol Multidisciplinar de Melanoma|Merck Sharp & Dohme LLC|Astellas Pharma Inc | Melanoma | 2025-06-10 | PHASE2 |
| NCT06904573 | Sun Yat-sen University | Advanced Urothelial Carcinoma|Probiotics|Immunotherapy | 2025-01-01 | PHASE2 |
| NCT05014139 | Astellas Pharma Global Development, Inc.|Seagen, a wholly owned subsidiary of Pfizer | Urinary Bladder Neoplasms|Carcinoma in Situ|Carcinoma Transitional Cell|Non-muscle Invasive Bladder Cancer|NMIBC | 2021-12-07 | PHASE1 |
| NCT04225117 | Astellas Pharma Global Development, Inc.|Seagen Inc.|Merck Sharp & Dohme LLC | Locally Advanced or Metastatic Malignant Solid Tumors | 2020-03-10 | PHASE2 |
| NCT03606174 | Mirati Therapeutics Inc. | Urothelial Carcinoma|Urothelial Carcinoma Bladder|Urothelial Carcinoma Ureter|Urothelial Carcinoma of the Renal Pelvis and Ureter|Urothelial Carcinoma Urethra | 2018-09-11 | PHASE2 |
| NCT07566156 | Astellas Pharma Global Development, Inc.|Pfizer | Urothelial Cancer|Urinary Bladder Neoplasms | 2026-05-11 | PHASE3 |
| NCT06493552 | Vasgene Therapeutics, Inc | Muscle-Invasive Bladder Carcinoma|Metastatic Urothelial Carcinoma | 2025-03-15 | PHASE2|PHASE3 |
| NCT06145308 | Peking Union Medical College|Peking University Hospital of Stomatology | Salivary Gland Carcinoma|Precision Therapy | 2023-08-15 | PHASE2 |
| NCT07346053 | Guliz Ozgun|British Columbia Cancer Agency | Advanced Bladder Cancer | 2026-05 | PHASE3 |
| NCT06311214 | National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm | 2025-03-18 | PHASE2 |
| NCT03924895 | Merck Sharp & Dohme LLC|Seagen Inc.|Astellas Pharma Global Development, Inc. | Urinary Bladder Cancer, Muscle-invasive | 2019-07-24 | PHASE3 |
| NCT06891560 | Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc. | Adenoid Cystic Carcinoma | 2025-03-31 | PHASE2 |
| NCT06553885 | H. Lee Moffitt Cancer Center and Research Institute|Astellas Pharma Inc | Metastatic Colorectal Cancer|Hepatocellular Carcinoma | 2025-04-01 | PHASE2 |
| NCT06862219 | Astellas Pharma Global Development, Inc.|Pfizer | Metastatic Urothelial Carcinoma | 2025-06-21 | PHASE4 |
| NCT07087860 | Mayo Clinic | Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis and Ureter Urothelial Carcinoma|Refractory Bladder Urothelial Carcinoma|Refractory Renal Pelvis and Ureter Urothelial Carcinoma|Stage IV Bladder Cancer AJCC v7|Stage IV Renal Pelvis and Ureter Cancer AJCC v7 | 2025-08-01 | PHASE2 |
| NCT04136808 | Astellas Pharma Global Development, Inc.|Seagen Inc. | Locally Advanced or Metastatic Urothelial Carcinoma (UC) | | |
| NCT05656235 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | High Grade Urothelial Carcinoma|Bladder Cancer|Urothelial Carcinoma Bladder | 2024-11-25 | PHASE2 |
| NCT06483334 | Merck Sharp & Dohme LLC | Metastatic Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma | 2024-07-17 | PHASE1|PHASE2 |
| NCT06041503 | National Cancer Institute (NCI) | Adenocarcinoma of the Bladder|Squamous Cell Carcinoma of the Bladder|Testicular Germ Cell Tumors | 2026-01-20 | PHASE2 |
| NCT06764095 | Mayo Clinic | Locally Advanced Bladder Urothelial Carcinoma|Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis and Ureter Urothelial Carcinoma|Stage III Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | 2025-01-08 | PHASE4 |
| NCT04963153 | National Cancer Institute (NCI) | Locally Advanced Bladder Urothelial Carcinoma|Locally Advanced Renal Pelvis Urothelial Carcinoma|Locally Advanced Ureter Urothelial Carcinoma|Locally Advanced Urethral Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Recurrent Bladder Urothelial Carcinoma|Recurrent Renal Pelvis Urothelial Carcinoma|Recurrent Ureter Urothelial Carcinoma|Recurrent Urethral Urothelial Carcinoma|Recurrent Urothelial Carcinoma|Stage IIIB Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8 | 2022-07-07 | PHASE1 |
| NCT05915351 | University of Kansas Medical Center | Pancreatic Ductal Adenocarcinoma|Pancreas Adenocarcinoma|Pancreas Cancer | 2023-06-30 | PHASE2 |
| NCT07183319 | University of Oklahoma|Natera, Inc. | Urothelial Carcinoma | 2026-01-19 | PHASE2 |
| NCT05868265 | Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc. | Urothelial Carcinoma | 2023-06-02 | PHASE2 |
| NCT04754191 | University of Utah|Astellas Pharma Inc | Metastatic Castration-resistant Prostate Cancer | 2022-06-05 | PHASE2 |
| NCT05756569 | Emory University|National Cancer Institute (NCI)|Seagen Inc.|Astellas Pharma Inc|Merck Sharp & Dohme LLC | Bladder Squamous Cell Carcinoma|Locally Advanced Bladder Carcinoma|Malignant Renal Pelvis Neoplasm|Malignant Ureter Neoplasm|Malignant Urethral Neoplasm|Metastatic Bladder Carcinoma|Stage III Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Unresectable Bladder Carcinoma|Urachal Adenocarcinoma|Bladder Adenocarcinoma | 2023-09-26 | PHASE2 |
| NCT04700124 | Merck Sharp & Dohme LLC|Seagen Inc.|Astellas Pharma Inc | Bladder Cancer | 2021-04-21 | PHASE3 |
| NCT04223856 | Astellas Pharma Global Development, Inc.|Merck Sharp & Dohme LLC|Seagen Inc. | Urothelial Cancer | 2020-03-30 | PHASE3 |
| NCT07139977 | William Bradley|Astellas Pharma Inc | Endometrial Cancer | 2026-04-01 | PHASE2 |
| NCT06305767 | Merck Sharp & Dohme LLC|ModernaTX, Inc. | Bladder Cancer | 2024-03-28 | PHASE1|PHASE2 |
| NCT05614739 | Eli Lilly and Company | Urinary Bladder Neoplasms|Neoplasm Metastasis|Ureteral Neoplasms | 2023-01-12 | PHASE1 |
| NCT05097599 | Strata Oncology|Merck Sharp & Dohme LLC|Pfizer|Gilead Sciences | Cancer|Advanced Solid Tumor | 2022-04-29 | PHASE2 |
| NCT03070990 | Astellas Pharma Inc|Seagen Inc. | Metastatic Urothelial Cancer | 2017-04-24 | PHASE1 |
| NCT06724159 | Spanish Oncology Genito-Urinary Group|MFAR | Genitourinary Cancers | 2024-12-13 | |
| NCT03869190 | Hoffmann-La Roche|Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas | Urothelial Carcinoma|Bladder Cancer | 2019-06-01 | PHASE1|PHASE2 |
| NCT05524545 | ALX Oncology Inc. | Bladder Cancer|Urothelial Carcinoma | 2022-11-02 | PHASE1 |
| NCT02091999 | Astellas Pharma Global Development, Inc.|Seagen Inc. | Metastatic Urothelial Cancer and Other Malignant Solid Tumors | 2014-05-14 | PHASE1 |
| NCT05775471 | Jonsson Comprehensive Cancer Center|Merck Sharp & Dohme LLC|Seagen Inc. | Renal Pelvis and Ureter Urothelial Carcinoma | 2024-06-26 | PHASE2 |
| NCT06011954 | Astellas Pharma Korea, Inc.|Seagen Inc. | Urothelial Cancer | 2023-11-01 | |
| NCT04724018 | Dana-Farber Cancer Institute|Gilead Sciences | Urothelial Cancer|Metastatic Urothelial Carcinoma|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Bladder Cancer | 2021-05-20 | PHASE1|PHASE2 |
| NCT04878029 | Emory University|Exelixis|National Cancer Institute (NCI) | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation|Locally Advanced Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Unresectable Urothelial Carcinoma | 2021-07-23 | PHASE1 |
| NCT03219333 | Astellas Pharma Inc|Seagen Inc. | Carcinoma, Transitional Cell|Urinary Bladder Neoplasms|Urologic Neoplasms|Renal Pelvis Neoplasms|Urothelial Cancer|Ureteral Neoplasms|Urethral Neoplasms | 2017-10-08 | PHASE2 |
| NCT04995419 | Astellas Pharma China, Inc.|Seagen Inc. | Metastatic Urothelial Cancer | 2021-07-22 | PHASE2 |
| NCT04960709 | AstraZeneca | Muscle Invasive Bladder Cancer | 2021-08-05 | PHASE3 |
| NCT03288545 | Astellas Pharma Global Development, Inc.|Merck Sharp & Dohme LLC|Seagen Inc. | Carcinoma, Transitional Cell|Urinary Bladder Neoplasms|Urologic Neoplasms|Renal Pelvis Neoplasms|Urothelial Cancer|Ureteral Neoplasms|Urethral Neoplasms | 2017-10-11 | PHASE1|PHASE2 |
| NCT07221942 | Fox Chase Cancer Center|United States Department of Defense | Metastatic Urothelial Carcinoma|Unresectable Urothelial Carcinoma|Advanced Urothelial Carcinoma | 2026-01-23 | PHASE2 |
| NCT04887870 | Mirati Therapeutics Inc. | Advanced or Metastatic Solid Malignancies | 2021-06-29 | PHASE2|PHASE3 |
| NCT06302569 | Giuseppe Procopio | Bellini Carcinoma|Collecting Duct Carcinoma|Renal Medullary Carcinoma | 2025-05-30 | PHASE2 |
| NCT05239624 | Memorial Sloan Kettering Cancer Center|Astellas Pharma US, Inc.|Seagen Inc.|Merck Sharp & Dohme LLC | Urothelial Carcinoma | 2022-06-02 | PHASE2 |
| NCT03474107 | Astellas Pharma Global Development, Inc.|Seagen Inc. | Ureteral Cancer|Urothelial Cancer|Bladder Cancer | 2018-06-27 | PHASE3 |
| NCT07287995 | Astellas Pharma Global Development, Inc. | Locally Advanced or Metastatic Malignant Solid Tumors | 2026-02-05 | PHASE1|PHASE2 |
| NCT05923190 | Fox Chase Cancer Center | Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma | 2023-06-14 | PHASE2 |